Brexit Opportunity for Intas and Aurobindo as Novo and Sanofi Warn on Supplies — Panjiva
MENU

Supply Chain Research

Brexit Opportunity for Intas and Aurobindo as Novo and Sanofi Warn on Supplies

Brexit 175 European Union 822 Health Care 351 India 509 Trade Deals 999 U.S. 5313 United Kingdom 366

A “no-deal” Brexit could accelerate existing the supply chain trend of increased purchases from outside the EU. Pharmaceutical suppliers including Novo Nordisk and Sanofi have warned of shortages in the event of that a withdrawal agreement and related customs arrangements are not finalized. That may explain the turnaround in British imports of medicines to a 2.4% year over year rise after an average 13.2% decline in the prior three months. Over the longer term supplies of pharmaceuticals from outside the EU are already increasing. For example imports from India climbed 15.8% in the 12 mo...

Copyright © 2024 Panjiva Supply Chain Intelligence, a product offering from S&P Global Market Intelligence Inc. All rights reserved.